Alpha-synuclein-induced neurodegeneration is exacerbated in PINK1 knockout mice

Neurobiology of Aging

Volumn 35, Issue 11, 2014, Pages 2625-2636

  Oliveras Salvá, Marusela ^a   Macchi, Francesca ^a   Coessens, Valérie ^a   Deleersnijder, Angélique ^b   Gérard, Melanie ^b   Van der Perren, Anke ^a   Van den Haute, Chris ^a,c   Baekelandt, Veerle ^a  

^a KU LEUVEN UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c KU LEUVEN   (Belgium)

Author keywords

AAV; Aggregation; Knockdown; Knockout; Mouse; Neurodegeneration; Parkinson's disease; Phosphorylation; PINK1; Synuclein

Indexed keywords

ALPHA SYNUCLEIN; PHOSPHOTRANSFERASE; PTEN INDUCED KINASE 1; UNCLASSIFIED DRUG; PROTEIN AGGREGATE; PROTEIN KINASE; PTEN-INDUCED PUTATIVE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CELL DEATH; CONTROLLED STUDY; DISEASE ACTIVITY; DOWN REGULATION; FEMALE; IN VIVO STUDY; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NERVE DEGENERATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SENSITIVITY ANALYSIS; SUBSTANTIA NIGRA; ANIMAL; APOPTOSIS; CELL CULTURE; DEFICIENCY; DEGENERATIVE DISEASE; DISEASE COURSE; GENE EXPRESSION; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTATION; NERVE CELL; PARKINSON DISEASE; PATHOLOGY; PHOSPHORYLATION; PROTEINOSIS;

ALPHA-SYNUCLEIN; ANIMALS; APOPTOSIS; CELLS, CULTURED; DISEASE PROGRESSION; DOWN-REGULATION; GENE EXPRESSION; HUMANS; MICE, KNOCKOUT; MUTATION; NEURODEGENERATIVE DISEASES; NEURONS; PARKINSON DISEASE; PHOSPHORYLATION; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN KINASES; SUBSTANTIA NIGRA;

EID: 84918820798     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.04.032     Document Type: Article

References (64)

1. Akundi R.S., Huang Z., Eason J., Pandya J.D., Zhi L., Cass W.A., Sullivan P.G., Bueler H. Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One 2011, 6:e16038.
2. Anderson J.P., Walker D.E., Goldstein J.M., de Laat R., Banducci K., Caccavello R.J., Barbour R., Huang J., Kling K., Lee M., Diep L., Keim P.S., Shen X., Chataway T., Schlossmacher M.G., Seubert P., Schenk D., Sinha S., Gai W.P., Chilcote T.J. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J.Biol. Chem. 2006, 281:29739-29752.
3. Anichtchik O., Diekmann H., Fleming A., Roach A., Goldsmith P., Rubinsztein D.C. Loss of PINK1 function affects development and results in neurodegeneration in zebrafish. J.Neurosci. 2008, 28:8199-8207.
4. Butler E.K., Voigt A., Lutz A.K., Toegel J.P., Gerhardt E., Karsten P., Falkenburger B., Reinartz A., Winklhofer K.F., Schulz J.B. The mitochondrial chaperone protein TRAP1 mitigates alpha-synuclein toxicity. PLoS Genet. 2012, 8:e1002488.
5. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
6. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Exp. Cell Res. 2008, 314:2076-2089.
7. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
8. Deleersnijder A., Van Rompuy A.S., Desender L., Pottel H., Buee L., Debyser Z., Baekelandt V., Gerard M. Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation. J.Biol. Chem. 2011, 286:26687-26701.
9. Deng H., Jankovic J., Guo Y., Xie W., Le W. Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem. Biophys. Res. Commun. 2005, 337:1133-1138.
10. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J.Biol. Chem. 2008, 283:9089-9100.
11. Farrer M.J. Genetics of Parkinson disease: paradigm shifts and future prospects. Nat. Rev. Genet. 2006, 7:306-318.
12. Fujiwara H., Hasegawa M., Dohmae N., Kawashima A., Masliah E., Goldberg M.S., Shen J., Takio K., Iwatsubo T. Alpha-synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
13. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain 2006, 129:1720-1731.
14. Gao G., Vandenberghe L.H., Wilson J.M. New recombinant serotypes of AAV vectors. Curr. Gene Ther. 2005, 5:285-297.
15. Gasser T. Mendelian forms of Parkinson's disease. Biochim. Biophys. Acta 2009, 1792:587-596.
16. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proc. Natl. Acad. Sci. U.S.A 2008, 105:11364-11369.
17. Geisler S., Holmstrom K.M., Skujat D., Fiesel F.C., Rothfuss O.C., Kahle P.J., Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat. Cell Biol. 2010, 12:119-131.
18. George S., Mok S.S., Nurjono M., Ayton S., Finkelstein D.I., Masters C.L., Li Q.X., Culvenor J.G. Alpha-synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced alpha-synuclein and PINK1 levels after rotenone treatment. J.Mol. Neurosci. 2010, 42:243-254.
19. Geraerts M., Michiels M., Baekelandt V., Debyser Z., Gijsbers R. Upscaling of lentiviral vector production by tangential flow filtration. J.Gene Med. 2005, 7:1299-1310.
20. Gerard M., Deleersnijder A., Daniëls V., Schreurs S., Munck S., Reumers V., Pottel H., Engelborghs Y., Van den Haute C., Taymans J.M., Debyser Z., Baekelandt V. Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology. J.Neurosci. 2010, 30:2454-2463.
21. Gispert S., Ricciardi F., Kurz A., Azizov M., Hoepken H.H., Becker D., Voos W., Leuner K., Müller W.E., Kudin, A.P., Kunz W.S., Zimmermann A., Roeper J., Wenzel D., Jendrach M., García-Arencíbia M., Fernández-Ruiz J., Huber L., Rohrer, H., Barrera, M., Reichert A.S., Rüb U., Chen A., Nussbaum R.L., Auburger G. Parkinson phenotype in aged PINK1-deficient mice is accompanied by progressive mitochondrial dysfunction in absence of neurodegeneration. PLoS One 2009, 4:e5777.
22. Glasl L., Kloos K., Giesert F., Roething A., Di Benedetto, B., Huhn R., Zhang J., Hafen U., Zerle J., Hofmann A., de Angelis M.H., Winklhofer K.F., Hölter S.M., Vogt Weisenhorn D.M., Wurst W. Pink1-deficiency in mice impairs gait, olfaction and serotonergic innervation of the olfactory bulb. Exp. Neurol. 2012, 235:214-227.
23. Gundersen H.J., Jensen E.B. The efficiency of systematic sampling in stereology and its prediction. J.Microsc. 1987, 147:229-263.
24. Haque M.E., Thomas K.J., D'Souza C., Callaghan S., Kitada T., Slack R.S., Fraser P., Cookson M.R., Tandon A., Park D.S. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. U.S.A 2008, 105:1716-1721.
25. Haque M.E., Mount M.P., Safarpour F., Abdel-Messih E., Callaghan S., Mazerolle C., Kitada T., Slack R.S., Wallace V., Shen J., Anisman H., Park D.S. Inactivation of Pink1 gene invivo sensitizes dopamine-producing neurons to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and can be rescued by autosomal recessive Parkinson disease genes, Parkin or DJ-1. J.Biol. Chem. 2012, 287:23162-23170.
26. He L., Hannon G.J. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. Genet. 2004, 5:522-531.
27. Heeman, B., Van den Haute C., Aelvoet S.A., Valsecchi F., Rodenburg R.J., Reumers V., Debyser Z., Callewaert G., Koopman W.J., Willems P.H., Baekelandt V. Depletion of PINK1 affects mitochondrial metabolism, calcium homeostasis and energy maintenance. J.Cell Sci. 2011, 124:1115-1125.
28. Kamp F., Exner N., Lutz A.K., Wender N., Hegemann J., Brunner B., Nuscher B., Bartels T., Giese A., Beyer K., Eimer S., Winklhofer K.F., Haass C. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J. 2010, 29:3571-3589.
29. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. U.S.A 2007, 104:11441-11446.
30. Klinkenberg M., Thurow N., Gispert S., Ricciardi F., Eich F., Prehn J.H., Auburger G., Kogel D. Enhanced vulnerability of PARK6 patient skin fibroblasts to apoptosis induced by proteasomal stress. Neuroscience 2010, 166:422-434.
31. Liu W., Vives-Bauza C., Acín-Peréz R., Yamamoto A., Tan Y., Li Y., Magrané J., Stavaranche M.A., Shaffer S., Chang S., Kaplitt M.G., Huang X.Y., Beal M.F., Manfredi G., Li C. PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson's disease. PLoS One 2009, 4:e4597.
32. Matsuda N., Sato S., Shiba K., Okatsu K., Saïsho K., Sou Y.S., Saiki S., Kawajiri S., Sato F., Kimura M., Komatsu M., Hattori N., Tanaka K. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J.Cell Biol. 2010, 189:211-221.
33. McBride J.L., Boudreau R.L., Harper S.Q., Staber P.D., Monteys A.M., Martins I., Gilmore B.L., Burstein H., Peluso R.W., Polisky B., Carter B.J., Davidson B.L. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc. Natl. Acad. Sci. U.S.A 2008, 105:5868-5873.
34. Murakami T., Moriwaki Y., Kawarabayashi T., Nagai M., Ohta Y., Geduchi K., Kurata T., Moromoto N., Takehisa Y., Matsubara E., Ikeda M., Harigaya Y., Shoji M., Takahashi R., Abe K. PINK1, a gene product of PARK6, accumulates in alpha-synucleinopathy brains. J.Neurol. Neurosurg. Psychiatry 2007, 78:653-654.
35. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 2010, 8:e1000298.
36. Oliveras-Salvá M., Van Rompuy A.S., Heeman B., Van den Haute C., Baekelandt V. Loss-of-function rodent models for Parkin and PINK1. J.Parkinson's Dis. 2011, 1:229-251.
37. Oliveras-Salva M., Van der Perren A., Casadei N., Stroobants S., Nuber S., D'Hooge R., Van den Haute C., Baekelandt V. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol. Neurodegener. 2013, 8:44.
38. Osorio L., Gijsbers R., Oliveras-Salva M., Michiels A., Debyser Z., Van den Haute C., Baekelandt V. Viral vectors expressing a single microRNA-based short-hairpin RNA result in potent gene silencing invitro and invivo. J.Biotechnol. 2014, 169:71-81.
39. Ostrerova-Golts N., Petrucelli L., Hardy J., Lee J.M., Farer M., Wolozin B. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J.Neurosci. 2000, 20:6048-6054.
40. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65:1272-1284.
41. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
42. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press, San Diego.
43. Plun-Favreau H., Klupsch K., Moisoi N., Gandhi S., Kjaer S., Frith D., Harvey K., Deas E., Harvey R.J., McDonald N., Wood N.W., Martins L.M., Downward J. The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1. Nat. Cell Biol. 2007, 9:1243-1252.
44. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidativestress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol. 2007, 5:e172.
45. Sallinen V., Kolehmainen J., Priyadarshini M., Toleikyte G., Chen Y.C., Panula P. Dopaminergic cell damage and vulnerability to MPTP in Pink1 knockdown zebrafish. Neurobiol. Dis. 2010, 40:93-101.
46. Samann J., Hegermann J., von Gromoff E., Eimer S., Baumeister R., Schmidt E. Caenorhabditits elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J.Biol. Chem. 2009, 284:16482-16491.
47. Samaranch L., Lorenzo-Betancor O., Arbelo J.M., Ferrer I., Lorenzo E., Irigoyen J., Pastor M.A., Marrero C., Isla C., Herrera-Henriquez J., Pastor P. PINK1-linked parkinsonism is associated with Lewy body pathology. Brain 2010, 133:1128-1142.
48. Sandebring A., Thomas K.J., Beilina A., van der Brug M., Cleland M.M., Ahmad R., Miller D.W., Zambrano I., Cowburn R.F., Behbahani H., Cedazo-Mingues A., Cookson M.R. Mitochondrial alterations in PINK1 deficient cells are influenced by calcineurin-dependent dephosphorylation of dynamin-related protein 1. PLoS One 2009, 4:e5701.
49. Schmitz C., Hof P.R. Design-based stereology in neuroscience. Neuroscience 2005, 130:813-831.
50. Shin J.H., Ko H.S., Kang H., Lee Y., Lee Y.I., Pletinkova O., Troconso J.C., Dawson V.L., Dawson T.M. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011, 144:689-702.
51. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
52. Sun D., Melegari M., Sridhar S., Rogler C.E., Zhu L. Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. Biotechniques 2006, 41:59-63.
53. Taymans J.M., Van den Haute C., Baekelandt V. Distribution of PINK1 and LRRK2 in rat and mouse brain. J.Neurochem. 2006, 98:951-961.
54. Todd A.M., Staveley B.E. Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson's disease. Genome 2008, 51:1040-1046.
55. Todd A.M., Staveley B.E. Expression of Pink1 with alpha-synuclein in the dopaminergic neurons of Drosophila leads to increases in both lifespan and healthspan. Genet. Mol. Res. 2012, 11:1497-1502.
56. Valente E.M., Salvi S., Ialongo T., Marongiu R., Elia A.E., Caputo V., Romito L., Albanese A., Dallapiccola B., Bentivoglio A.R. PINK1 mutations are associated with sporadic early-onset parkinsonism. Ann. Neurol. 2004, 56:336-341.
57. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., González-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
58. Van den Haute C., Eggermont K., Nuttin B., Debyser Z., Baekelandt V. Lentiviral vector-mediated delivery of short hairpin RNA results in persistent knockdown of gene expression in mouse brain. Hum. Gene Ther. 2003, 14:1799-1807.
59. Van der Perren A., Toelen J., Carlon M., Van den Haute C., Coun F., Heeman B., Reumers V., Vandenberghe L.H., Wilson J.M., Debyser Z., Baekelandt V. Efficient and stable transduction of dopaminergic neurons in rat substantia nigra by rAAV 2/1, 2/2, 2/5, 2/6.2, 2/7, 2/8 and 2/9. Gene Ther. 2011, 18:517-527.
60. Wang H.L., Chou A.H., Wu A.S., Chen S.Y., Weng Y.H., Kao Y.C., Yeh T.H., Chu P.J., Lu C.S. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochim. Biophys. Acta 2011, 1812:674-684.
61. Xi Y., Ryan J., Noble S., Yu M., Yilbas A.E., Ekker M. Impaired dopaminergic neuron development and locomotor function in zebrafish with loss of pink1 function. Eur. J. Neurosci. 2010, 31:623-633.
62. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. U.S.A 2006, 103:10793-10798.
63. Zhou H., Falkenburger B.H., Schulz J.B., Tieu K., Xu Z., Xia X.G. Silencing of the Pink1 gene expression by conditional RNAi does not induce dopaminergic neuron death in mice. Int. J. Biol. Sci. 2007, 3:242-250.
64. Zhou C., Huang Y., Shao Y., May J., Prou D., Perier C., Dauer W., Schon E.A., Przedborski S. The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc. Natl. Acad. Sci. U.S.A 2008, 105:12022-12027.